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Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anti-
coagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2
might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in
clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2
than to patients with lower scores.
Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral
Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective
global registry of patients with newly diagnosed AF and 1 stroke risk factor. We compared baseline
clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA pre-
scription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and  2. Among 17,465
anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients
an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2.
The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and
27.5% in those with scores 2.
Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection
may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the
absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anti-
coagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hy-
pothesis is currently being tested in a randomized controlled trial.
Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377,
NCT01468701, and NCT01671007.
© 2021 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Sc (Stroke Medicine), PhD,
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For many decades, vitamin-K antagonists (VKA) were the only
anticoagulant choice for patients with non-valvular atrial fibrilla-
tion (NVAF), which remains one of the major etiologies of ischemic
stroke1. The achievement and maintenance of a therapeutic inter-
national normalized ratio (INR) in VKA-treated patients can bes is an open access article under the CC BY-NC-ND license (http://creativecommons.
ticoagulant selection in relation to the SAMe-TT2R2 score in patients
logy, https://doi.org/10.1016/j.hjc.2020.11.009
Table 1
Baseline characteristics and their standardized differences by baseline SAMe-TT2R2 score for eligible anticoagulated patients in Phase III
SAMe-TT2R2  2 SAMe-TT2R2 > 2 Standardized difference
n ¼ 11,884 n ¼ 5,581
Demographics
Age, mean ± SD, years 72.4 ± 9.4 68.3 ± 11.4 0.3920
Female gender 4,936 (41.5%) 2,915 (52.2%) 0.2156
Race
White 11,351 (95.5%) 1,546 (27.7%) 1.9450
Asian 330 (2.8%) 2,181 (39.1%) 0.9972
Black/African American 20 (0.2%) 300 (5.4%) 0.3213
Insurance status
Private 1,717 (14.4%) 835 (15.0%) 0.0145
Statutory/federal insurance 8,871 (74.6%) 4,002 (71.7%) 0.0664
Self-pay/no coverage 429 (3.6%) 416 (7.5%) 0.1687
Comorbidities
Body mass index (kg/m2), mean ± SD 29.39 ± 6.41 27.76 ± 6.40 0.2553
Dyslipidemia 5,077 (42.7%) 2,040 (36.6%) 0.1264
Hepatic disease 91 (0.8%) 142 (2.5%) 0.1398
Congestive heart failure 2,424 (20.4%) 1,437 (25.7%) 0.1273
NYHA I 203 (8.4%) 138 (9.6%) 0.0430
NYHA II 1,325 (54.7%) 759 (52.8%) 0.0370
NYHA III 520 (21.5%) 316 (22.0%) 0.0131
NYHA IV 45 (1.9%) 60 (4.2%) 0.1359
Ejection fraction 40% 973 (40.1%) 596 (41.5%) 0.0272
Diabetes mellitus 2,574 (21.7%) 1586 (28.4%) 0.1565
Arterial hypertension 8,950 (75.3%) 4,331 (77.6%) 0.0540
Abnormal kidney function 181 (1.5%) 97 (1.7%) 0.0170
Previous stroke 1,135 (9.6%) 656 (11.8%) 0.0715
Transient ischemic attack 651 (5.5%) 185 (3.3%) 0.1057
Pulmonary embolism 70 (0.6%) 39 (0.7%) 0.0137
Deep venous thrombosis 168 (1.4%) 53 (0.9%) 0.0430
Non-CNS arterial embolism 49 (0.4%) 20 (0.4%) 0.0087
Smoking
Nonsmoker 6,821 (57.4%) 3,078 (55.2%) 0.0453
Current smoker 180 (1.5%) 1,369 (24.5%) 0.7277
Past smoker 4,482 (37.7%) 985 (17.6%) 0.4602
Alcohol abuse (8 Units/week) 883 (7.4%) 357 (6.4%) 0.0407
Coronary artery disease 2,052 (17.3%) 998 (17.9%) 0.0162
Myocardial infarction 1,127 (9.5%) 476 (8.5%) 0.0333
Periphery arterial disease 348 (2.9%) 165 (3.0%) 0.0017
Prior bleeding 610 (5.1%) 252 (4.5%) 0.0288
Cancer 1392 (11.7%) 404 (7.2%) 0.1532
Creatinine clearance (ml/min), mean ± SD 86.0 ± 200.5 80.3 ± 39.9 0.0394
Creatinine clearance <15 ml/min 70 (0.6%) 42 (0.8%) 0.0200
Creatinine clearance 15 to <30 ml/min 188 (1.6%) 122 (2.2%) 0.0444
Creatinine clearance 30 to <50 ml/min 1,235 (10.4%) 722 (12.9%) 0.0793
Creatinine clearance 50 to <80 ml/min 3,854 (32.4%) 1,723 (30.9%) 0.0335
Creatinine clearance 80 ml/min 4,215 (35.5%) 1,893 (33.9%) 0.0326
Type of NVAF
Paroxysmal 6,204 (52.2%) 3,115 (55.8%) 0.0725
Persistent 4,354 (36.6%) 1,947 (34.9%) 0.0365
Permanent 1,326 (11.2%) 519 (9.3%) 0.0614
Categorization of NVAF
Symptomatic 3,475 (29.2%) 1,930 (34.6%) 0.1148
Minimally symptomatic 3,930 (33.1%) 1,893 (33.9%) 0.0180
Asymptomatic 4,479 (37.7%) 1,758 (31.5%) 0.1304
Type of site
GP/primary care 600 (5.0%) 337 (6.0%) 0.0433
Specialist office 3,856 (32.4%) 1,341 (24.0%) 0.1878
Community hospital 3,679 (31.0%) 1,731 (31.0%) 0.0013
University hospital 3,439 (28.9%) 1,910 (34.2%) 0.1139
Outpatient health care center 184 (1.5%) 79 (1.4%) 0.0110
Anticoagulation clinic 74 (0.6%) 28 (0.5%) 0.0162
Physician specialty
GP/PCP/Geriatrician 651 (5.5%) 148 (2.7%) 0.1435
Cardiologist 9,702 (81.6%) 5,077 (91.0%) 0.2739
Internist 594 (5.0%) 144 (2.6%) 0.1269
Neurologist 320 (2.7%) 133 (2.4%) 0.0197
CHADS2 score, mean ± SD 1.9 ± 1.2 1.9 ± 1.1 0.0222
CHADS2 score ¼ 0 964 (8.1%) 394 (7.1%) 0.0397
CHADS2 score ¼ 1 4,051 (34.1%) 1,809 (32.4%) 0.0355
CHADS2 score  2 6,868 (57.8%) 3,378 (60.5%) 0.0557
CHA2DS2-VASc score, mean ± SD 3.2 ± 1.5 3.2 ± 1.5 0.0364
CHA2DS2-VASc score ¼ 1 1,408 (11.8%) 718 (12.9%) 0.0309
CHA2DS2-VASc score  2 10,476 (88.2%) 4,863 (87.1%) 0.0309
HAS-BLED, mean ± SD 1.3 ± 0.8 1.2 ± 0.9 0.1571
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Table 1 (continued )
SAMe-TT2R2  2 SAMe-TT2R2 > 2 Standardized difference
n ¼ 11,884 n ¼ 5,581
HAS-BLED <3 9,846 (82.9%) 4,616 (82.7%) 0.0038
HAS-BLED 3 898 (7.6%) 381 (6.8%) 0.0282
Treatment with amiodarone 825 (6.9%) 1640 (29.4%) 0.6085
Antithrombotic prescription
VKA alone 2,795 (23.5%) 1,291 (23.1%) 0.0092
VKA þ antiplatelets 470 (4.0%) 272 (4.9%) 0.0447
NOAC alone 7,434 (62.6%) 3,486 (62.5%) 0.0019
NOAC þ antiplatelets 1,185 (10.0%) 532 (9.5%) 0.0148
Figure 1. Proportion of patients treated with VKA and NOAC by baseline SAMe-TT2R2 score and region.
Figure 2. Proportion of patients treated with VKA and NOAC by baseline SAMe-TT2R2
score and enrollment year.
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narrow therapeutic window, need for frequent INR measurements
with consequent dose adjustments, and food-drug and drug-drug
interactions2.
Common clinical factors determine if a patient can achieve
effective and safe anticoagulation control on VKAs. The SAMe-TT2R23
score was developed to help identify those at high-risk for poor
anticoagulation control and thus higher risk of stroke or peripheral
embolism as estimated by the time in therapeutic INR range (TTR).
The SAMe-TT2R2 score consists of the following: Sex (female), Age
(<60 years); Medical history (2 of the following: hypertension,
diabetes, coronary artery disease/myocardial infarction, peripheral
arterial disease, congestive heart failure, previous stroke, pulmo-
nary disease, hepatic, or renal disease); Treatment (interacting
drugs like amiodarone for rhythm control) [all 1 point]; current
Tobacco use (2 points); and Race (2 points for non-Caucasian)3.
Patients with a SAMe-TT2R2 score >2 could best avoid a “trial of
VKA” and start directly with a non-vitamin-K-antagonist oral
anticoagulant (NOAC).
The recent 2020 Guidelines of the European Society of Cardi-
ology about the management of atrial fibrillation suggest that the
SAMe-TT2R2 score could be used to aid decision-making: patients
with a score of >2 points are prone to low TTR while on VKA and
can be monitored more closely with more frequent INR measure-
ments or can be supported with more intensive education or
counselling to improve TTR. Alternatively, if there are concerns,
they may skip a “trial of VKA” and start directly with a NOAC4.
In this context, we hypothesized that VKAs may be less
frequently prescribed in patients with NVAF and a SAMe-TT2R2
score of >2 as compared to patients with a score of 0-2. We tested
this hypothesis in a large, contemporary, prospective, global
registry of newly diagnosed NVAF patients with 1 stroke risk
factors.
Table 2
Log-binomial regression analysis for the prediction of VKA prescription. Only patients who were anticoagulated were included in the analysis
Patients N VKA use N (%) NOAC use N (%) Univariate analysis Multivariate analysis
Relative risk (95% CI)
for prescription of VKA use
Relative risk (95% CI)
for prescription of VKA use
Baseline SAMe-TT2R2
Score >2 5581 1563 (28.0) 4018 (72.0) 1.019 (0.968, 1.073) 0.907 (0.856, 0.961)
Score 2 11884 3265 (27.5) 8619 (72.5) 1.0 (ref) 1.0 (ref)
Region
Asia 2609 798 (30.6) 1811 (69.4) 1.022 (0.957, 1.091) 1.138 (1.054, 1.226)
Europe 9182 2747 (29.9) 6435 (70.1) 1.0 (ref) 1.0 (ref)
North America 4261 734 (17.2) 3527 (82.8) 0.576 (0.535, 0.619) 0.604 (0.560, 0.650)
Latin America 1413 549 (38.9) 864 (61.1) 1.299 (1.206, 1.395) 1.355 (1.254, 1.461)
Type of AF
Paroxysmal 9319 2179 (23.4) 7140 (76.6) 1.0 (ref) 1.0 (ref)
Persistent 6301 1968 (31.2) 4333 (68.8) 1.336 (1.268, 1.407) 1.271 (1.207, 1.339)
Permanent 1845 681 (36.9) 1164 (63.1) 1.579 (1.470, 1.692) 1.372 (1.276, 1.472)
BMI class
<18.5 199 58 (29.1) 141 (70.9) 1.015 (0.802, 1.250) 1.035 (0.820, 1.269)
18.5<25 4484 1288 (28.7) 3196 (71.3) 1.0 (ref) 1.0 (ref)
25<30/Missing 6807 1907 (28.0) 4900 (72.0) 0.975 (0.919, 1.036) 0.992 (0.934, 1.053)
30<35 3559 954 (26.8) 2605 (73.2) 0.933 (0.869, 1.002) 0.982 (0.914, 1.055)
35 2416 621 (25.7) 1795 (74.3) 0.895 (0.824, 0.971) 1.031 (0.948, 1.119)
Prior bleeding
Yes 862 248 (28.8) 614 (71.2) 1.043 (0.933, 1.158) 1.044 (0.936, 1.156)
No/Unknown 16603 4580 (27.6) 12023 (72.4) 1.0 (ref) 1.0 (ref)
Alcohol abuse
Yes(8U/week) 1240 300 (24.2) 940 (75.8) 0.867 (0.781, 0.957) 0.881 (0.795, 0.972)
No(<8U/week/Unknown) 16225 4528 (27.9) 11697 (72.1) 1.0 (ref) 1.0 (ref)
Cancer
Yes 1796 478 (26.6) 1318 (73.4) 0.959 (0.883, 1.038) 1.050 (0.968, 1.135)
No/Unknown 15669 4350 (27.8) 11319 (72.2) 1.0 (ref) 1.0 (ref)
Medical treatment reimbursed by
Selfpay/No coverage 845 221 (26.2) 624 (73.8) 0.944 (0.837, 1.056) 0.785 (0.696, 0.880)
Not selfpay/Unknown 16620 4607 (27.7) 12013 (72.3) 1.0 (ref) 1.0 (ref)
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The Global Registry on Long-Term Oral Antithrombotic Treat-
ment in Patients with Atrial Fibrillation (GLORIA-AF) was designed
to generate evidence on patients with recently diagnosed NVAF
treated in routine clinical practice. The aim of this multinational,
multicenter, prospective, noninterventional registry is to provide
long-term effectiveness and safety data on NOAC and VKA for
stroke prevention in patients with NVAF in nearly 50 countries5.
The design of GLORIA-AF, a global, noninterventional registry
program with 3 phases, has been described in detail previously5.
Phase III consists of a cross-sectional and comparative analyses part
involving a 3-year follow-up of all patients independent of
antithrombotic therapy. Ethical approvals were obtained from the
Institutional Review Boards as required at participating sites. The
GLORIA-AF study is listed at Clinicaltrials.gov (Nos. NCT01937377,
NCT01468701, and NCT01671007).
The phase III of GLORIA-AF enrolled adult patients with newly
diagnosed NVAF (i.e., NVAF diagnosed within 3 months of the
baseline visit; Latin America <4.5 months) and a CHA2DS2-VASc
score of1 between 2014 and 2016. Patients withmechanical heart
valves, prior VKA therapy for >60 days, life-expectancy 1 year at
recruitment, a comorbidity other than NVAF for which the chronic
use of VKAs is indicated and NVAF due to a generally reversible
cause were excluded. The CHADS2 and CHA2DS2-VASc scores were
used to assess the thromboembolic risk of the patients. The HAS-
BLED bleeding score was used to assess the bleeding risk6. Pa-
tients were recruited from outpatient settings from university
hospitals, community hospitals, specialist offices, and general
practice offices. Sites were chosen to reflect physicians who typi-
cally identify and manage patients with newly diagnosed NVAF
cases in each participating country.4
2.1. Data collection and quality control
All clinical datawere collected and processed using aweb-based
external vendor managed Infosario Outcome EDC® system to
ensure that data were complete, accurate, internally consistent,
logical, and in compliance with the requirements of the protocol.
Study data were entered into the EDC system by the study staff
using a secured network and the study physician electronically
signed the case report forms to confirm accuracy and completeness
of the entered information. Extensive data quality standards were
in place to address any systematic data issues identified.2.2. Statistical Analysis
Baseline data were summarized descriptively. Continuous vari-
ables were reported as mean and standard deviation. Categorical
variables were reported as absolute frequencies and percentages.
SAMe-TT2R2 scores were derived from the patient characteristics at
baseline. Baseline characteristics for patients treated with oral an-
ticoagulants were described based on the SAMe-TT2R2 score (>2
versus2). Rather than relying on statistical significance testing (p-
values), emphasis was put on estimation using confidence intervals
(CI) to measure effect size and to gauge precision, given that P-
values confine the interpretation of the results as significant and
non-significant, whereas CI move the interpretation of the results
to the effect size and its range of plausible values given by the data
under study. P-values are dependent on sample size, however,
standardized differences are independent of sample size and it is an
intuitive index to compare baseline characteristics. Interpretation
was based on the value of standardized difference. The focus will be
on the variables with highest standardized differences, while
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between the groups7.
We performed a log-binomial regression analysis to estimate
risk ratios in the cohort of patients who were anticoagulated to
identify the association between the SAMe-TT2R2 score and pre-
scription of VKA. We use the term “probability ratio” rather than
“risk ratio” as our measure describes drug use rather than adverse
outcomes. Both univariate and multivariate log-binomial regres-
sion analyses were performed to evaluate the crude as well as the
adjusted probability ratios together with 95% CIs. The variables
included in this analysis were the SAMe-TT2R2 score and other
covariates, which are not SAMe-TT2R2 components, as follows: the
type of AF (paroxysmal vs. persistent vs. permanent), body mass
index class, reimbursement status, geographical region (Asia,
Europe, North America, and Latin America), other comorbidities
[prior bleeding and cancer], and alcohol abuse. No covariate se-
lection procedure was employed, rather all variables that might
have an impact on the prescription pattern were included in the
model. Statistical analyses were performed with the SAS software
version 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
The baseline characteristics and their standardized differences
by baseline SAMe-TT2R2 score are summarized in Table 1. Among
21,597 patients who were enrolled in 38 countries, there were
21,248 who were eligible for the analysis. Of these, 17,465 (82.2%)
were treated with oral anticoagulation (45.0% women) and were
included in the analysis. Among OAC-treated patients, 4,828 (27.6%)
received VKA and 12,637 (72.4%) received NOAC. Out of 17,465 OAC-
treated patients, 11,884 (68.0%) patients had an SAMe-TT2R2 score
of 2 and 5,581 (32.0%) with a score of >2.
Patients with an SAMe-TT2R2 score of 2 were older (mean age
(±SD) 72.4 ± 9.4 vs 68.3 ± 11.4) and were more often men (58.5% vs
47.8%) as compared to those with SAMe-TT2R2 score >2. The mean
CHADS2 score was 1.9 ± 1.1 and the mean CHA2DS2-VASc was
3.2 ± 1.5 in both SAMe-TT2R2 groups. The mean HAS-BLED was
1.3 ± 0.8 in patients with the SAMe-TT2R2 score of 2 and 1.2 ± 0.9
for patients with SAMe-TT2R2 score of >2.
3.1. Clinical risk profile and SAMe-TT2R2 score
Patients from Europe accounted for 60.8% of those with an
SAMe-TT2R2 score of 2; 38.9% and 35.0% of patients with an
SAMe-TT2R2 score >2 were from Asia and Europe, respectively.
Fewer patients in the SAMe-TT2R2 score of 2 underwent NVAF
ablation (0.9% vs 4.2%) and there was a higher prevalence of
hyperlipidemia (42.7% vs 36.6%) and cancer (11.7% vs 7.2%) than
those with a score of >2. There was high prevalence of congestive
heart failure (25.7% vs 20.4%), diabetes mellitus (28.4% vs 21.7%),
hepatic disease (2.5% vs 0.8%), and chronic kidney disease (27.1% vs
22.0%) in an SAMe-TT2R2 score >2 versus thosewith an SAMe-TT2R2
score 2.
3.2. SAMe-TT2R2 score and VKA use: Regional differences
The proportion of patients treated with VKAs was 28.0% with an
SAMe-TT2R2 score of >2 and 27.5% with a score of 2. Patients from
Europe and Latin America who had an SAMe-TT2R2 score >2 were
less often prescribed VKA when compared with an SAMe-TT2R2
score 2 (21.0% vs. 28.2%, for Europe, standardized
difference: 0.169; 27.8% vs. 41.1%, for Latin America, standardized
difference: 0.283). Patients from North America with an SAMe-
TT2R2 score >2 were more often prescribed VKA when compared5
with those with an SAMe-TT2R2 score 2 (14.3% vs. 9.6%, respec-
tively, standardized difference: 0.147) (Fig. 1).
3.3. SAMe-TT2R2 score and VKA use: Enrolment year
There were no important differences in the prescription rate of
VKAs between patients with an SAMe-TT2R2 score >2 versus those
with a score of 2 with regard to the enrollment year (26.4% vs.
23.5%, for 2014, standardized difference: 0.067; 23.0% vs. 26.4%, for
2015, standardized difference: 0.079; 22.3% vs. 19.1%, for 2016,
standardized difference: 0.079) (Fig. 2).
3.4. Multivariable analysis
In the multivariable analysis, patients with an SAMe-TT2R2 score
>2 were less frequently prescribed VKA when compared with pa-
tients with a score 2 (adjusted probability ratio 0.907; 95%CI:
(0.856 and 0.961). Factors associatedwith an increased prescription
of VKA use were the geographical region and type of NVAF
(Table 2).
4. Discussion
This is the first global study to assess the association between
the SAMe-TT2R2 score and the type of oral anticoagulant use in a
large, prospective, multinational cohort of nonvalvular AF patients
anticoagulated in routine clinical practice. We found no clear as-
sociation between the SAMe-TT2R2 score and anticoagulant
selection.
The lack of clear association between the SAMe-TT2R2 score and
anticoagulant selection may indicate that other factors, not
captured entirely by the SAMe-TT2R2 likely have more influence on
prescriptive choices in clinical practice. Such a factor may be the
safety and efficacy profile of VKAs and NOACs. There is solid evi-
dence from randomized controlled trials as well as from real-world
studies, showing that NOACs are safer and at least as effective as
VKAs8-10. Accordingly, current clinical practice guidelines recom-
mend NOACs in preference to VKA11-13. Because of overwhelming
evidence favoring NOACs over VKAs, treating physicians may have
largely adopted the related recommendations and prefer to start
directly with an NOAC among NOAC-eligible NVAF patients, even in
patients with a favorable SAMe-TT2R2 scorewhowould be expected
to maintain a good level of anticoagulation control on VKA. This is
in line with recent reports of sharply increasing trends of NOAC
prescription over VKA worldwide14-17.
Another potential explanation for the results of our analysis is
that although several validation studies in different populations
suggest that the SAMe-TT2R2 score can predict the quality of anti-
coagulation in NVAF patients, there is still no trial evidence that an
SAMe-TT2R2-guided strategy for the selection of the type of anti-
coagulation in NVAF patients has an impact on clinical outcomes of
efficacy and safety. In this context, a large, randomized trial that
assesses a SAMe-TT2R2-guided strategy on the quality of anti-
coagulation and on clinical outcomes (e.g., thromboembolism and
bleeding) would determine its utility in routine clinical practice.
Such an ongoing trial, the TREATS-AF trial, is being conducted in
Thailand18. The geographical variation regarding VKA prescription
may be conceivably related to local prescription and reimburse-
ment policies, but this needs to be confirmed in future studies.
4.1. Limitations
While we did not perform region-specific analyses, the large
sample size of prospectively recruited patients from nearly 50
G. Ntaios, M.V. Huisman, H.-C. Diener et al. Hellenic Journal of Cardiology xxx (xxxx) xxxcountries with extensive data quality review and broad physician
and site selection worldwide enhanced the value of this study.
5. Conclusion
In this large, prospective, multinational cohort of nonvalvular AF
patients anticoagulated in routine clinical practice, we found no
clear association between the SAMe-TT2R2 score and anticoagulant
selection. The lack of clear association between the SAMe-TT2R2
score and anticoagulant selection may be attributed to the relative
efficacy and safety profiles between NOACs and VKAs as well as to
the absence of trial evidence that an SAMe-TT2R2-guided strategy
for the selection of the type of anticoagulation in NVAF patients has
an impact on clinical outcomes of efficacy and safety. The latter
hypothesis is currently being tested in a randomized, controlled
trial.
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